Abstract # 13248 Poster # 72:

Scheduled for Thursday, August 9, 2018 06:00 PM-08:00 PM: (Chula Vista ) Poster Presentation


M. N. Flores1, M. Lopez1, M. Mireles1, A. Salmon2, S. Tardif2,3 and C. Ross1,2,3
1Texas A&M University- San Antonio, 1 University Way, san antonio, Texas 78224, USA, 2University of Texas Health Science Center San Antonio, 3Southwest National Primate Research Center, Texas Biomedical Research Institute
     Rapamycin has previously been shown to extend lifespan in rodent models. Prior to transitioning the treatment to humans it is important to evaluate healthspan measures in a non-human primate model. Rapamycin is currently being evaluated in a lifespan study with marmosets (Callithrix jacchus); cohort 1 consisting of 12 rapamycin dosed animals and 9 eudragit control animals began treatment March 2016, cohort 2 consisting of 6 rapamycin dosed and 8 controls began in January 2017. To evaluate ambulatory and social behavior 10-minute behavior observations noting leaping, hanging, movement, placement in the cage and interactions with their pairmate have been collected for each individual once a month. After 12 months of treatment geriatric animals (>9 years old) exhibited fewer transitions between quadrants of the cage, and used the locomotor behavior of leaping significantly less than young animals (p<0.04). There were no significant differences in the amount of time spent moving or at rest, or in social behaviors when comparing geriatric and young animals, and no differences were found for animals receiving rapamycin. Evaluating the same behaviors in cohort 1 after 24 months of rapamycin treatment we found that age differences persist in leaping, transitions within the cage, and hanging behavior; however, no differences exist in association with rapamycin treatment to date. Supported by NIH P30 AG013319, R01 AG050797.